11:34 AM EST - Immunoprecise Antibodies Ltd. : Announced the launch of a new research initiative. As part of its Research and Development Program, the Company has begun working on a project in collaboration with an established biotech company that is developing human therapeutics. ImmunoPrecise Antibodies is applying its RapidPrime™ protocol to the humanization of monoclonal antibodies in mice and rats. ImmunoPrecise's proprietary RapidPrime™ Method identifies positive monoclonal antibodies in as little as 32 days. ImmunoPrecise Antibodies
shares V.IPA are trading up $0.03 at $1.12.
